Eupraxia Pharmaceuticals (EPRX) Stock Price, Quote, News & History | Benzinga

Eupraxia Pharmaceuticals Inc (EPRX) Stock Price, Quote, News & History

EPRXNASDAQ

Trade with Public

Trade with Public

$7.36

-0.07-0.94%

At close: Aug 27, 5:00 PM EST

$7.49

0.131.77%

After Hours: 7:26 AM EST

OverviewNews Earnings Forecast Events Price Targets Financials Sentiment Compare Stock Report

Key Statistics

Open

$7.42

Close

$7.36

Volume / Avg.

208.63K / 364.93K

Day Range

$7.30 - $7.53

52 Wk Range

5.07 - 9.32

Market Cap

$494.89M

P/E Ratio

-

Dividend Yield

-

Exchange

NASDAQ

RSI

62

Short Interest

-

Days to Cover

28.76

Recent Eupraxia Pharmaceuticals Inc News

VNET Group, Akari Therapeutics And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session

US stock futures up, VNET Group shares down 3.8% after reporting Q1 loss of $(1.20) per share on $390.133 million sales. Other stocks also fall.

Avi Kapoor

Why JOYY Shares Are Trading Higher By 12%; Here Are 20 Stocks Moving Premarket

Gainers: PHGE +97.3%, ARTL +74.8%, QTEX +52.4%, MNTX +34.4%, HLIT +28.3%, WOK +25%, CPSH +24.7%, CODX +22.7%, MDAI +22%. Losers: AKTX -25.2%, RYOJ -18.6%, DEVS -18.6%, AKAN -17%, ADTX -16.3%, LFS -15.6%

Avi Kapoor

This SailPoint Analyst Begins Coverage On A Bullish Note; Here Are Top 3 Initiations For Thursday

Top analysts changed outlook on top names. See all rating changes at benzinga.com/analyst-stock-ratings. Considering SAIL stock? Here's what analysts say.

Avi Kapoor

Eupraxia Pharmaceuticals Boasts $900 Million Peak Sales Potential: Analyst

William Blair starts Eupraxia at Outperform as the analyst flags unmet need and sizable market potential.

Vandana Singh

Semtech To Rally Around 18%? Here Are 10 Top Analyst Forecasts For Tuesday

Wall Street analysts changed outlook on top names: Morgan Stanley raised Lemonade's PT to $85, Mizuho cut Canadian Solar's PT to $19, Piper Sandler raised Tandem Diabetes' PT to $33, Stifel increased Ichor's PT to $55, Needham raised Semtech's PT to $105, HC Wainwright cut Eupraxia Pharma's PT to $11, Evercore ISI Group raised National Storage Affiliates Trust's PT to $41.

Avi Kapoor

Financials

Quarterly

Annual

Name

Revenue Change
Gross Change
EBITDA Change
EBIT Change
Earnings Change

Cash Flows

Operating Cash Flow (TTM)

-37.47M

Investing Cash Flow (TTM)

-80.48M

Financing Cash Flow (TTM)

151.45M

Free Cash Flow (TTM)

-38.23M

Capital Expenditure (TTM)

-753.72K

Net Change in Cash (TTM)

33.50M

Analyst Trends and Forecast

2

Mar

1

Apr

2

May

1

Jun

Buy

Hold

Sell

Strong Sell

Analyst Rating and Forecast

4.2

Buy

Strong Buy

Buy

Hold

Sell

Strong Sell

Valuation Metrics

Enterprise Value

$377.12M

PE Ratio (TTM)

-

PE Ratio (FWD)

-

PEG Ratio (TTM)

-

PS Ratio (TTM)

-

PB Ratio (TTM)

4.53

Earnings Yield % (TTM)

-13.78%

Earnings Yield % (FWD)

-6.79%

EV / EBITDA (TTM)

-

Price / EBITDA (TTM)

-

Price / Free Cash Flow (TTM)

-

Book Value / Share

$1.64

Company Debt

Total Debt

-

LT Debt

-

LT Debt Issuance (TTM)

-

LT Debt Repayment (TTM)

-

Total Cash

$52.43M

Debt to Equity

0.02

Issuance of Debt (TTM)

-

Repayment of Debt (TTM)

-

Key Statistics

Open

$7.42

Close

$7.36

Volume / Avg.

208.63K / 364.93K

Day Range

$7.30 - $7.53

52 Wk Range

5.07 - 9.32

Market Cap

$494.89M

P/E Ratio

-

Dividend Yield

-

Exchange

NASDAQ

RSI

62

Short Interest

-

Days to Cover

28.76

About

Sector

Health Care

Industry

Biotechnology

Eupraxia Pharmaceuticals Inc is a clinical-stage biotechnology company focused on the development of locally delivered, extended-release alternatives to existing pharmaceuticals. Its product EP-104 is used for the treatment of osteoarthritis and eosi...

Show More

Edge Rankings

Stock Score Locked: Want to See it?

Benzinga Rankings give you vital metrics on any stock – anytime.

Reveal Full Score

Compare

EPS worse than industry

Earnings Per Share

EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.

Earnings Per Share

EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.

EPS worse than industry

FAQ

Q

How do I buy Eupraxia Pharmaceuticals (EPRX) stock?

A

You can purchase shares of Eupraxia Pharmaceuticals (NASDAQ:EPRX) through any online brokerage.

View our list of the best stock brokerages

Q

Who are Eupraxia Pharmaceuticals (EPRX) competitors?

A

Other companies in Eupraxia Pharmaceuticals’s space includes: AbbVie Inc (NYSE:ABBV), Amgen Inc (NASDAQ:AMGN), Gilead Sciences Inc (NASDAQ:GILD), Vertex Pharmaceuticals Inc (NASDAQ:VRTX) and Regeneron Pharmaceuticals Inc (NASDAQ:REGN).

Q

What is the forecast, or price target, for Eupraxia Pharmaceuticals (EPRX) stock?

A

Eupraxia Pharmaceuticals has a consensus price target of $16.20.

Q

What is the current price for Eupraxia Pharmaceuticals (EPRX)?

A

The stock price for Eupraxia Pharmaceuticals (NASDAQ: EPRX) is $7.49 last updated August 27, 2026 at 7:26 AM EDT.

Q

Does Eupraxia Pharmaceuticals (EPRX) pay a dividend?

A

There are no upcoming dividends for Eupraxia Pharmaceuticals.

Q

When is Eupraxia Pharmaceuticals (NASDAQ:EPRX) reporting earnings?

A

Eupraxia Pharmaceuticals does not have any upcoming earnings scheduled.

Q

Is Eupraxia Pharmaceuticals (EPRX) going to split?

A

There is no upcoming split for Eupraxia Pharmaceuticals.

Q

What sector and industry does Eupraxia Pharmaceuticals (EPRX) operate in?

A

Eupraxia Pharmaceuticals is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.